INTEGRATED BIOPHARMA INC 8-K

What Happened
Integrated Biopharma, Inc. announced its financial results for the quarter ended December 31, 2025 via a press release dated February 11, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K (Item 2.02), and incorporated the release by reference into the filing.

Key Details

• Filing date: February 11, 2026 (Form 8-K).
• Reporting period: quarter ended December 31, 2025.
• The press release announcing the results is furnished as Exhibit 99.1 and incorporated by reference.
• The Form 8-K entry is Item 2.02 (Results of Operations and Financial Condition); Exhibit listing appears under Item 9.01.

Why It Matters
This 8-K signals that the company has publicly released its latest quarterly results (earnings, revenue and other financial metrics) for investors to review. The Form 8-K itself points to the press release for the detailed figures and management commentary—investors should read Exhibit 99.1 and the company’s subsequent SEC filings for the specific revenue, net income (or loss), cash position, and any forward guidance that could affect valuation or near-term trading.